Orthopedic Regenerative Surgical Products Market (2026 - 2033)

Orthopedic Regenerative Surgical Products Market Summary

The global orthopedic regenerative surgical products market size was valued at USD 5.7 billion in 2025 and is projected to grow from USD 6.1 billion in 2026 to USD 11.0 billion in 2033, at a CAGR of 8.8% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 40.0% in 2025. The rising prevalence of orthopedic conditions, such as arthritis, technological advancements, and the growing number of orthopedic surgeries, are key factors fueling market growth. 

Moreover, rising R&D investments and activities are expected to drive market growth over the forecast period. According to an article published by the U.S. National Library of Medicine, a clinical study on Platelet Rich Plasma (PRP) injections was conducted in Italy by the Azienda Ospedaliero-Universitaria Consorziale Policlinico. This study focused on treating knee osteoarthritis in adults aged 40 to 81 years. Orthopedic issues, such as osteoarthritis, among the older population are significant drivers of demand for related products.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

A 2025 study published in Clinical Rheumatology indicates that knee osteoarthritis remains one of the most prevalent musculoskeletal disorders worldwide. Earlier research, supported by China's National Natural Science Foundation and reported in The Lancet, estimated that approximately 22.9% of individuals aged 40 and older were affected by knee osteoarthritis, representing around 654.1 million people globally in 2020. Recent analyses suggest that the global burden of knee osteoarthritis is continuing to rise due to aging populations, obesity, and increased life expectancy. This trend is significantly boosting the demand for orthopedic regenerative surgical products and advanced treatment options. The prevalence of knee osteoarthritis is expected to grow during the forecast period, driven by factors such as obesity, sedentary lifestyles, and an aging population, further stimulating market growth.

Moreover, several innovations, including reservoir-type orthobiologics and advanced, miniaturized orthobiologics patches, are enabling accurate medication dosing. The demand for orthobiologics is projected to increase during the forecast period as technology supporting targeted organ medicine delivery progresses. Additionally, organizations have faced operational challenges due to supply chain disruptions, travel restrictions, business closures, employee illness or quarantines, and social distancing protocols.

For instance, in the U.S., public health bodies suggested postponing elective surgeries to meet the demands of coronavirus patients and prevent cross-infection. Technological advancements and the growing adoption of emerging technologies, such as viscosupplements, stem cells, and Platelet Rich Plasma (PRP) therapies, along with increasing R&D efforts, are projected to drive market demand. The use of regenerative medicine therapies for musculoskeletal disorders continues to grow as clinical evidence supporting orthobiologics, stem cell therapies, and tissue engineering approaches expands.

Recent studies highlight growing attention toward personalized regenerative treatments for cartilage, bone, tendon, and joint repair, reflecting strong acceptance of regenerative medicine among researchers, clinicians, and patients. In 2025, several scientific publications highlighted the rapid advancement of musculoskeletal regenerative medicine and the growing adoption of biologically driven treatment strategies to improve tissue healing and functional recovery. Such developments are expected to support the growth of the orthopedic regenerative surgical products market during the forecast period.

The response was even more positive among individuals with personal experience of these therapies. Stem cell and PRP-based therapies are at the forefront of regenerative medicine research, focusing on the restoration and repair of damaged tissues, trauma, and osteoarthritis. In 2025, a prospective, randomized study published in JAAOS Global Research & Reviews reported that amniotic tissue injections provided significant improvements in pain relief and physical function in patients with severe knee osteoarthritis compared with corticosteroid injections.

Analyst Perspective

The orthopedic regenerative surgical products market is witnessing steady growth, driven by the rising prevalence of musculoskeletal disorders and increasing demand for minimally invasive treatments. Growing adoption of biologics, stem cell therapies, bone graft substitutes, and tissue engineering technologies is supporting market expansion. These products help improve tissue repair, accelerate healing, and enhance patient outcomes. Companies focusing on product innovation, clinical advancements, and diversified regenerative solutions are expected to gain a competitive advantage.

Product Insights

Based on products, the market is categorized into synthetic, cell-based, allografts, and viscosupplements. The viscosupplements segment dominated the market, accounting for over 40.0% of total revenue in 2025, owing to the increased incidence of osteoarthritis and knee pain. Factors such as obesity, external injury, excessive exercise, genetic predisposition, and aging further contribute to knee osteoarthritis, thereby driving product demand. Key players in the market are launching new products to maintain their position. For instance, in August 2025, Ono Pharmaceutical and Seikagaku Corporation entered into a definitive agreement to co-develop and market Gel-One, a hyaluronic acid viscosupplement currently undergoing Phase III clinical studies in Japan for the treatment of osteoarthritis.

The allografts segment is anticipated to witness the fastest CAGR during the forecast period, owing to the increasing utilization of allografts, including off-the-shelf cartilage, osteochondral allografts, fresh-frozen meniscal allografts, and soft tissue allografts. According to Allograft Company JRF Ortho, allografts offer several benefits, including enhanced bone healing, reduced surgical time, fewer complications, and faster recovery. JRF Ortho, a company focused on the sports medicine market, has distributed over 20,000 fresh OCA grafts.  

Application Insights

Based on applications, the market is segmented into cartilage and tendon repair, orthopedic pain management, joint reconstruction, trauma repair, and others. The joint reconstruction segment dominated the market, accounting for the largest revenue share of around 35.0% in 2025, driven by the rising adoption of regenerative solutions, growing surgical procedures, and technological advancements. For instance, the Clarix line of surgical allografts from Amniox Medical, Inc., is used in orthopedic surgeries such as arthroplasty, reconstruction, and trauma, as well as in soft-tissue repair.

The cartilage and tendon repair segment is anticipated to grow at a lucrative CAGR during the forecast period, attributed to several factors, including the increasing number of older patients, rising trauma cases, and growing applications in sports medicine. For example, MACI, developed by Vericel, is used to treat cartilage defects resulting from overuse injuries, general wear and tear, and muscle weakness in the knee. MACI generated net revenue of approximately USD 239.5 million for the fiscal year ended December 2025,

End Use Insights

Based on end-use, the market is further segmented into hospitals, ambulatory surgical centers (ASCs), and others. The hospital segment accounted for the largest revenue share, at around 50.0%, in 2025. Hospitals are the primary revenue source for the healthcare sector and an integral part of the industry, which propels innovation and research. The dominance of the hospital segment is attributable to the highest volumes of orthopedic treatments being performed in hospital settings. For instance, in 2025, the Hospital for Special Surgery (HSS) in New York continued to maintain its position as one of the world's leading orthopedic hospitals, performing more than 40,000 surgical procedures annually and supporting extensive research and clinical adoption of advanced orthopedic and regenerative treatment technologies.

The ASC segment is expected to showcase the fastest CAGR during the forecast period. This growth is attributed to increased use of products for treatments and pain management in ASCs. Furthermore, the rising number of ASCs for treating orthopedic patients is expected to fuel market growth over the forecast period. According to data published by the Ambulatory Surgery Center Association (ASCA) in March 2025, based on Centers for Medicare & Medicaid Services (CMS) records, there were approximately 171 Medicare-certified ASCs in Washington, 896 in California, 517 in Florida, 423 in Georgia, and 497 in Texas. These numbers are projected to increase during the forecast period.

Regional Insights

North America held the largest revenue share of over 40.0% in 2025. The region's dominance can be attributed to several factors, including the presence of key players, technologically advanced healthcare facilities in Canada and the U.S., and an aging population. According to Statistics Canada, the population aged 65 years and older reached approximately 8.1 million people in 2025. Similarly, Europe remains one of the oldest regions globally, with approximately 99 million people aged 65 years and over in 2025, representing 22% of the European Union's population, while the median age reached 44.9 years. These factors increase the risk of developing orthopedic illnesses, thereby driving the demand for products in the market.

To learn more about this report, Download Free Sample Report

APAC Orthopedic Regenerative Surgical Products Market Trends

The Asia Pacific market is expected to grow at a lucrative CAGR over the forecast period. The growth can be attributed to several factors, including regional expansion by key players, the development of healthcare infrastructure, and the increasing prevalence of orthopedic ailments, such as osteoarthritis. According to the Ministry of Health and Family Welfare of the Government of India and related epidemiological studies, the prevalence of osteoarthritis in India remains high, affecting approximately 22% to 38% of the population. In addition, according to the Australian Bureau of Statistics (ABS) National Health Survey 2023-24, approximately 3.7 million Australians (14.5% of the population) were living with arthritis in 2025. Furthermore, a significant proportion of patients continue to experience chronic pain and mobility limitations associated with the disease, supporting the demand for advanced orthopedic treatment options. All these factors contribute to the region’s growth.

Key Orthopedic Regenerative Surgical Products Market Companies Insights

Key players in the market are undertaking strategic initiatives, including product development & launches, regional expansion, R&D, and distribution network expansion, to maintain a competitive edge. Key players are also pursuing strategies, such as mergers & acquisitions and alliances, to strengthen their market presence.

Key Orthopedic Regenerative Surgical Products Companies

The following key companies have been profiled for this study on the orthopedic regenerative surgical products market.

• Anika Therapeutics, Inc.

• Vericel Corporation

• Baxter

• Zimmer Biomet

• Stryker

• Smith & Nephew

• AlloSource

• Amniox Medical, Inc.

• VSY Biotechnology

• Aptissen S.A.

• MiMedx

• Arthrex, Inc.

Recent Developments 

• In June 2025, Carisma Therapeutics and OrthoCellix, a wholly owned subsidiary of Ocugen, entered into a definitive merger agreement to create a clinical-stage company focused on regenerative cell therapies for orthopedic diseases. The combined entity is expected to advance NeoCart, an autologous cartilage implant technology designed to repair articular cartilage defects of the knee, thereby strengthening its position in the orthopedic regenerative medicine market.

• In December 2025, Organogenesis announced a successful FDA Type-B meeting for ReNu. It confirmed plans to initiate a rolling Biologics License Application (BLA) submission for the treatment of knee osteoarthritis pain. ReNu has received Regenerative Medicine Advanced Therapy (RMAT) designation and is supported by multiple Phase III clinical studies, highlighting continued advancement in orthopedic regenerative therapies.

Global Orthopedic Regenerative Surgical Products Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels, and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global orthopedic regenerative surgical products market report based on product, application, end-use, and region:

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Allografts

    • Amniotic Products

    • Others

  • Synthetic

  • Cell-based

  • Viscosupplements

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Orthopedic Pain Management

  • Trauma Repair

  • Cartilage & Tendon Repair

  • Joint Reconstruction

  • Others

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals

  • Ambulatory Surgical Centers

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia